Alto Neuroscience (ANRO) Change in Accured Expenses (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Change in Accured Expenses data on file, last reported at -$1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 35.1% year-over-year to -$1.8 million; the trailing twelve-month figure through Mar 2026 stood at $659000.0 (down 26.78% YoY), and the FY2025 full-year result was -$289000.0, down 107.21% from the prior year.
• Change in Accured Expenses declined to -$1.8 million in Q1 2026, from $1.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2025 to a low of -$2.7 million in Q1 2025.
• A 4-year average of $123692.3 and a median of $406000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 323.6% in 2025, while the deepest fall reached 765.27% in 2025.
• Tracing ANRO's Change in Accured Expenses over 4 years: stood at -$500000.0 in 2023, then jumped by 182.2% to $411000.0 in 2024, then soared by 323.6% to $1.7 million in 2025, then tumbled by 200.69% to -$1.8 million in 2026.
• Business Quant data shows ANRO's Change in Accured Expenses at -$1.8 million in Q1 2026, $1.7 million in Q4 2025, and $208000.0 in Q3 2025.